Auvin Stéphane
Université Paris Cité, INSERM NeuroDiderot, Paris, France.
APHP, Robert Debré University Hospital, Pediatric Neurology Department, CRMR Epilepsies Rares, EpiCare Member, Paris, France.
Epilepsy Behav Rep. 2024 Mar 16;26:100660. doi: 10.1016/j.ebr.2024.100660. eCollection 2024.
A case study of a child with childhood absence epilepsy and hyperactivity introduces the discussion around the psychiatric diagnosis, differential considerations, and pharmacologic treatment options for ADHD/hyperactivity in children with epilepsy. Most of the time, ADHD in children with epilepsy is an inattentive form. The assessment emphasizes the need to differentiate ADHD symptoms from other psychiatric comorbidities. This is also crucial to evaluate when symptoms emerged, their impact on daily life, and if it could be a potential medication side effect. Speaking about hyperactivity signs, differential diagnoses include anxiety disorders, autism spectrum disorders, learning disabilities, and thyroid disorders. Valproate use is associated with an exacerbation of attentional issues in childhood absence epilepsy, but there are also studies suggesting its possible role in hyperactivity symptoms. Regarding pharmacologic treatment, limited studies exist on ADHD management in children with epilepsy. Methylphenidate shows effectiveness without significant risk of epilepsy worsening. Atomoxetine and clonidine, usually use in ADHD, lack sufficient data for efficacy and safety in children with epilepsy and ADHD. Pharmacologic treatment should be a part of a global management plan that involves psychoeducation, environmental adaptations, and collaborative efforts between healthcare providers, caregivers, and schools.
一项关于患有儿童失神癫痫和多动的儿童的案例研究引发了围绕癫痫患儿注意力缺陷多动障碍(ADHD)/多动的精神科诊断、鉴别考虑因素和药物治疗选择的讨论。大多数情况下,癫痫患儿的ADHD表现为注意力不集中型。评估强调需要将ADHD症状与其他精神科合并症区分开来。这对于评估症状何时出现、其对日常生活的影响以及是否可能是潜在的药物副作用也至关重要。说到多动症状,鉴别诊断包括焦虑症、自闭症谱系障碍、学习障碍和甲状腺疾病。丙戊酸盐的使用与儿童失神癫痫中注意力问题的加重有关,但也有研究表明其在多动症状中可能发挥的作用。关于药物治疗,针对癫痫患儿ADHD管理的研究有限。哌甲酯显示出有效性,且癫痫恶化风险不高。通常用于ADHD的托莫西汀和可乐定,在癫痫合并ADHD的儿童中缺乏足够的疗效和安全性数据。药物治疗应成为一个全面管理计划的一部分,该计划包括心理教育、环境调整以及医疗保健提供者、照顾者和学校之间的协作努力。